SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. The company is headquartered in Aliso Viejo, California and currently employs 65 full-time employees. The company went IPO on 2026-02-06. The firm is focused on developing and commercializing long-term, drug delivery solutions for patients suffering from ophthalmic diseases. Its lead product candidate is SpyGlass Drug Delivery Platform with bimatoprost, which is designed to deliver three years of bimotic anti-inflammatory therapy to targeted tissues in the eye.
Mr. Patrick Mooney 2021 'den beri şirketle birlikte olan SpyGlass Pharma Inc 'in Chief Executive Officer 'ıdır.
SGP hissesinin fiyat performansı nasıl?
SGP 'in mevcut fiyatı $0 'dir, son işlem günde 0% azalmış etti.
SpyGlass Pharma Inc için ana iş temaları veya sektörler nelerdir?
SpyGlass Pharma Inc Pharmaceuticals endüstrisine ait ve sektör Health Care 'dir
SpyGlass Pharma Inc 'in piyasa değerlemesi nedir?
SpyGlass Pharma Inc 'in mevcut piyasa değerlemesi $NaN 'dir
SpyGlass Pharma Inc al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 6 analist SpyGlass Pharma Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 5 güçlü al, 3 al, 1 tut, 0 sat ve 5 güçlü sat içermektedir